CVRx, Inc. announced on July 16, 2025, that the Centers for Medicare and Medicaid Services (CMS) has proposed to maintain the Barostim implant procedure within the New Technology Ambulatory Payment Classification (APC) 1580. This proposal includes an associated payment of approximately $45,000 for procedures performed in the outpatient setting for 2026.
CMS is also soliciting comments regarding the potential need for a Level 6 Neurostimulator APC, indicating ongoing evaluation of appropriate reimbursement structures. The final 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) rule is expected to be published in November 2025, with an effective date of January 1, 2026.
This proposed continuation of favorable outpatient payment follows other positive reimbursement developments, including the assignment of Barostim to a higher-paying MS-DRG for inpatient procedures effective October 1, 2024, and the upcoming transition to Category I CPT codes for physician payments on January 1, 2026. These updates collectively reinforce Barostim's clinical value and support its broader market adoption.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.